MDAngle

• SGO 2025 SGO 2025: Impact of Precision Medicine in Endometrial Cancer   Dr Kathleen Moore emphasizes the need for a more nuanced approach to endometrial cancer treatment, particularly in the heterogeneous mismatch repair-proficient population.
  Medscape, April 03, 2025
• AAD 2025 Applying Key Lessons on HS From AAD 2025 to the Clinic   Dr. Christopher J. Sayed shares insights on the growing emphasis on personalized care for hidradenitis suppurativa.
  Medscape, March 28, 2025
• AAD 2025 New Hope for CSU: Applying Key Insights From AAD 2025   Dr Adam Friedman discusses the clinical impact of CSU updates, highlighting emerging therapies, dietary insights, and patient care strategies.
  Medscape, March 27, 2025
• Conference MDAngle: AAN 2025 Myasthenia Gravis Dr Nicholas Silvestri shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights on the impact of new myasthenia gravis research.
  Medscape, March 25, 2025
• AAN 2025: Anticipating New Approaches in Myasthenia Gravis   Dr Nicholas Silvestri looks ahead to new data on existing agents and emerging therapies for myasthenia gravis.
  Medscape, March 25, 2025
• Conference MDAngle: AAN 2025 Relapsing-Remitting Multiple Sclerosis Dr Pavan Bhargava shares AAN 2025 highlights, including anticipated presentations, quick takeaways, and insights into how new research in RRMS affects his patients.
  Medscape, March 24, 2025
• AAN 2025: Previewing New Data in the Management of RRMS   At AAN 2025, Dr Pavan Bhargava anticipates updates on diagnostic criteria, MRI techniques, biomarkers, treatments, and the role of diet in managing RRMS.
  Medscape, March 24, 2025
• SGO 2025 SGO 2025: Gaining Ground in Endometrial Cancer   Dr Kathleen Moore reports on new data including molecular insights from DUO-E, promising ADCs, and a targeted endocrine therapy approach with CDK4/6 inhibition.
  Medscape, March 21, 2025
• AAAAI 2025 AAAAI/WAO 2025: The Impact of Advancements in Allergy Care   Dr Ruchi Gupta reflects on the clinical implications of key highlights, including new CSU treatments, food allergy advances, and upcoming epinephrine options.
  Medscape, March 21, 2025
• ACTRIMS 2025 ACTRIMS 2025: Clinical Impact of New DMT Data in RRMS   Dr Annalisa Morgan reflects on incorporating new treatments discussed at the 2025 ACTRIMS Forum into clinical practice.
  Medscape, March 19, 2025
• AAD 2025 AAD 2025: New Excitement Around Hidradenitis Suppurativa   Dr Christopher J. Sayed describes how AAD 2025 showcased exciting advancements in hidradenitis suppurativa treatment.
  Medscape, March 17, 2025
• AAD 2025 Key Highlights From AAD 2025: Advances in CSU Management   Dr Adam Friedman recounts how AAD 2025 highlighted advancements in chronic spontaneous urticaria management, with discussion on new therapies and the role of diet.
  Medscape, March 13, 2025
• AAAAI 2025 AAAAI/WAO 2025: Updates in Anaphylaxis, Angioedema, and CSU   Dr Ruchi Gupta shares key updates including a new anaphylaxis definition, treatment advances, and emerging biologics for CSU.
  Medscape, March 07, 2025
• SGO 2025 Conference MDAngle: SGO 2025 Endometrial Cancer Dr Kathleen Moore provides SGO 2025 highlights, including anticipated presentations, quick takeaways, and insights into how the presented research will affect her patients.
  Medscape, March 06, 2025
• SGO 2025 SGO 2025: Previewing Advancements in Endometrial Cancer   Dr Kathleen Moore discusses key advancements in endometrial cancer from the past 2 years.
  Medscape, March 06, 2025
• ACTRIMS 2025 ACTRIMS 2025: Promising Advances in DMTs for RRMS   Dr Annalisa Morgan reflects on new data on DMTs for RRMS that highlighted the potential of BTK inhibitors such as tolebrutinib to reduce disability progression.
  Medscape, March 06, 2025
• The Impact of Health Disparities in IgA Nephropathy   Dr Andrew Bomback comments on how disparities in access to healthcare significantly delay the diagnosis and treatment of IgA nephropathy.
  Medscape, March 05, 2025
• IgA Nephropathy: Looking Back at an Early Patient Encounter   Dr Andrew Bomback reflects on how IgA nephropathy treatment has evolved from limited options like prednisone to a growing arsenal of targeted therapies.
  Medscape, March 05, 2025
• How a Career in Lecturing on IgA Nephropathy Has Evolved   Dr Pietro Canetta reflects on how the rapidly advancing field of IgA nephropathy research has transformed from limited knowledge to a dynamic area of scientific progress.
  Medscape, March 05, 2025
• Advice on Developing Opportunities in IgA Nephropathy   Dr Pietro Canetta emphasizes that early-career nephrologists must stay informed, seek expert guidance, and continuously learn to optimize patient care.
  Medscape, March 05, 2025